Inspire Medical Systems (NYSE:INSP) Given New $50.00 Price Target at Robert W. Baird

Key Points

• Robert W. Baird cut its price target on Inspire Medical Systems from $63 to $50 and maintained a "neutral" rating, implying about an 8.7% downside from the current share price.
• Inspire beat Q1 estimates with $0.10 EPS and $204.6M in revenue but materially lowered FY2026 guidance to $825M–$875M revenue and $0.75–$1.25 EPS, citing reimbursement/coding headwinds and a WISeR workflow disruption, which prompted the sharp market pullback.
• Analyst coverage is mixed — four Buys, fifteen Holds and one Sell — and MarketBeat's consensus is a Hold with a consensus target of $95.72, indicating divergence among analysts and continued caution.

Inspire Medical Systems (NYSE:INSP - Get Free Report) had its price target decreased by equities research analysts at Robert W. Baird from $63.00 to $50.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a "neutral" rating on the stock. Robert W. Baird's price target would indicate a potential downside of 8.70% from the stock's current price.

A number of other equities analysts have also recently issued reports on INSP. Royal Bank Of Canada restated a "sector perform" rating and set a $56.00 price objective on shares of Inspire Medical Systems in a report on Tuesday, April 14th. Piper Sandler cut Inspire Medical Systems from an "overweight" rating to a "neutral" rating and set a $55.00 price objective for the company. in a report on Tuesday. Stifel Nicolaus dropped their price objective on Inspire Medical Systems from $85.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 10th. Mizuho dropped their price objective on Inspire Medical Systems from $85.00 to $70.00 and set an "outperform" rating for the company in a report on Monday, April 13th. Finally, UBS Group set a $67.00 price objective on Inspire Medical Systems in a report on Friday, February 13th. Four analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Inspire Medical Systems has a consensus rating of "Hold" and a consensus target price of $95.72.

Inspire Medical Systems Stock Down 3.4%

INSP opened at $54.77 on Tuesday. The business has a fifty day moving average of $56.73 and a 200 day moving average of $79.64. Inspire Medical Systems has a 52-week low of $48.30 and a 52-week high of $163.35. The stock has a market cap of $1.58 billion, a P/E ratio of 11.00, a PEG ratio of 2.92 and a beta of 0.83.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The company had revenue of $204.58 million during the quarter, compared to analysts' expectations of $200.04 million. During the same quarter in the previous year, the business earned $0.10 EPS. Inspire Medical Systems's revenue was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Equities analysts anticipate that Inspire Medical Systems will post 1.82 EPS for the current fiscal year.

Institutional Investors Weigh In On Inspire Medical Systems

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Principal Financial Group Inc. raised its position in Inspire Medical Systems by 1.0% during the 1st quarter. Principal Financial Group Inc. now owns 126,788 shares of the company's stock valued at $6,540,000 after purchasing an additional 1,269 shares in the last quarter. Fifth Third Bancorp raised its position in Inspire Medical Systems by 1,794.4% during the 1st quarter. Fifth Third Bancorp now owns 6,441 shares of the company's stock valued at $332,000 after purchasing an additional 6,101 shares in the last quarter. New York State Teachers Retirement System raised its position in Inspire Medical Systems by 9.3% during the 1st quarter. New York State Teachers Retirement System now owns 23,599 shares of the company's stock valued at $1,217,000 after purchasing an additional 2,004 shares in the last quarter. Y Intercept Hong Kong Ltd raised its position in Inspire Medical Systems by 124.1% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 158,274 shares of the company's stock valued at $8,164,000 after purchasing an additional 87,639 shares in the last quarter. Finally, Leonteq Securities AG raised its position in Inspire Medical Systems by 187.3% during the 1st quarter. Leonteq Securities AG now owns 22,812 shares of the company's stock valued at $1,177,000 after purchasing an additional 14,873 shares in the last quarter. 94.91% of the stock is owned by institutional investors.

Inspire Medical Systems News Roundup

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 beat on EPS and revenue: Inspire reported $0.10 EPS (vs. expectations for a loss) and $204.6M in revenue, a modest year-over-year increase and slightly above consensus — shows underlying procedure demand held up in the quarter. Read More.
• Neutral Sentiment: Earnings call and details: Management discussed operational drivers and the timing impact of reimbursement/coding headwinds and the WISeR disruption — useful for modeling cadence but contained no offsetting near-term revenue levers. Read More.
• Negative Sentiment: Guidance cut materially lowers FY26 targets: Inspire lowered FY2026 revenue guidance to $825M–$875M and EPS to $0.75–$1.25, well below consensus — the reset is the main driver of the trader reaction and forces downward revisions to FY26 models. Read More.
• Negative Sentiment: Reimbursement/coding and WISeR disruption cited as causes: Management specifically blamed coding changes and disruption related to WISeR (workflow/servicing) for reduced procedure volumes and reimbursement uncertainty — this raises execution and policy risk until coding/reimbursement pathways normalize. Read More.
• Negative Sentiment: Market reaction and coverage: Media and market reports noted the sharp intraday pullback after guidance — highlights how the guidance reset dominated the beat and forced rapid re-pricing. Read More.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.